
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc has demonstrated a robust financial performance with a gross margin of 86.8%, exceeding consensus expectations and reflecting a 160 basis point year-over-year increase. The company experienced a 3% quarter-over-quarter increase in ordering facilities, reaching a total of 1,138, indicating strengthened market penetration. Furthermore, the anticipated revenue growth, driven by accelerated market share gains in minimally invasive glaucoma surgery (MIGS) and the quicker adoption of the TearCare System, suggests promising potential for future profitability.
Bears say
Sight Sciences Inc. experienced significant challenges in its financial performance, particularly within its Dry Eye segment, which reported revenue of $0.3 million, missing consensus estimates and reflecting an 81.0% growth but still indicative of underlying difficulties given a decline from previous periods. The company's revised GAAP EPS estimates for 2025 and 2026 have been significantly lowered, highlighting worsening profitability expectations amid anticipated revenue declines starting in the first quarter of 2025. Additionally, the impact of recently implemented Local Coverage Determinations (LCDs) has been noted to negatively influence OMNI volumes, contributing to a broader outlook of slowing revenue growth due to reimbursement headwinds.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares